With a spike in the new incidences of COVID-19 in India, hospitals have also been reporting a rare infection of mucormycosis, also called as black fungus, among people recovered from COVID-19. The infection is caused by exposure to mucor mould and it affects the sinuses, the brain and the lungs and may be life-threatening.
The Chemicals and Fertilizers Ministry has recently announced that the government is engaging with the drug manufacturers to ramp up the production of amphotericin B, an antifungal drug used for the treatment of mucormycosis.
“A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from mucormycosis, a post- COVID-19 complication,” the ministry said in a statement.
The supply position is expected to improve with extra imports of this drug and increase in its production domestically. The Department of Pharma has allocated the drug amongst the states based on expected supply that will be available from May 10 to May 31, 2021.
“The arrangements for supply will be monitored by the National Pharmaceuticals Pricing Authority (NPPA),” it added.